Storia in 2 fonti

GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market - The Korea Times

Korean health care company GC Wellbeing signed a strategic partnership agreement with U.S.-Israeli biotechnology firm Raziel Therapeutics to commer...

Raccontata da

koreatimes.co.kr

koreaherald.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

koreatimes.co.krStai leggendo2 mesi fa

GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market - The Korea Times

Korean health care company GC Wellbeing signed a strategic partnership agreement with U.S.-Israeli biotechnology firm Raziel Therapeutics to commer...

originale

koreaherald.com2 mesi fa

GC Wellbeing secures rights to next-gen fat-dissolving injection

GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fa

Leggi questa versione → originale

Timeline cronologica

venerdì 26 giugno 2026·koreatimes.co.kr
GC Wellbeing secures rights to obesity treatment RZL-012 for Korean market - The Korea Times
Korean health care company GC Wellbeing signed a strategic partnership agreement with U.S.-Israeli biotechnology firm Raziel Therapeutics to commer...
lunedì 29 giugno 2026·koreaherald.com
GC Wellbeing secures rights to next-gen fat-dissolving injection
GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fa